{"pmid":32303564,"title":"Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19.","text":["Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19.","Dozens of in vitro diagnostics (IVDs) have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) for the detection of SARS-CoV-2, but little has been studied to determine how well these assays perform using clinical specimens.....","J Clin Microbiol","Rhoads, Daniel D","Cherian, Sree S","Roman, Katharine","Stempak, Lisa M","Schmotzer, Christine L","Sadri, Navid","32303564"],"abstract":["Dozens of in vitro diagnostics (IVDs) have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) for the detection of SARS-CoV-2, but little has been studied to determine how well these assays perform using clinical specimens....."],"journal":"J Clin Microbiol","authors":["Rhoads, Daniel D","Cherian, Sree S","Roman, Katharine","Stempak, Lisa M","Schmotzer, Christine L","Sadri, Navid"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303564","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JCM.00760-20","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664431720455208960,"score":8.233237,"similar":[{"pmid":32260471,"title":"In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","text":["In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.","Diagnostics (Basel)","Vashist, Sandeep Kumar","32260471"],"abstract":["There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19."],"journal":"Diagnostics (Basel)","authors":["Vashist, Sandeep Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260471","week":"202015|Apr 06 - Apr 12","doi":"10.3390/diagnostics10040202","keywords":["COVID-19","SARS-CoV-2","diagnostics","immunoassays","lateral flow immunoassay (LFIA)","point-of-care (POC)","real-time reverse transcriptase polymerase chain (RT-PCR)"],"source":"PubMed","locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1663609715757678594,"score":284.38443},{"pmid":32277022,"title":"Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic.","text":["Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic.","Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of SARS-CoV-2 infection. To meet diagnostic needs as the pandemic grows, the US Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received US FDA EUA on March 12, 2020. The comparator was a standardized 3-hour SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target RT-PCR, which our laboratory has routinely used since January 2020 (Corman VM et al. EuroSurveill 25 (3):2000045). Cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall percent agreement of 99.6% and a kappa value of 0.98. A good correlation (r (2) = 0.96) between cycle threshold values for SARS-CoV-2 specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the UTM-RT system. Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 hours and in the midst of the COVID-19 pandemic if carefully planned and executed.","J Clin Microbiol","Poljak, Mario","Korva, Misa","Knap Gasper, Natasa","Fujs Komlos, Kristina","Sagadin, Martin","Ursic, Tina","Avsic Zupanc, Tatjana","Petrovec, Miroslav","32277022"],"abstract":["Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of SARS-CoV-2 infection. To meet diagnostic needs as the pandemic grows, the US Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received US FDA EUA on March 12, 2020. The comparator was a standardized 3-hour SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target RT-PCR, which our laboratory has routinely used since January 2020 (Corman VM et al. EuroSurveill 25 (3):2000045). Cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall percent agreement of 99.6% and a kappa value of 0.98. A good correlation (r (2) = 0.96) between cycle threshold values for SARS-CoV-2 specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the UTM-RT system. Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 hours and in the midst of the COVID-19 pandemic if carefully planned and executed."],"journal":"J Clin Microbiol","authors":["Poljak, Mario","Korva, Misa","Knap Gasper, Natasa","Fujs Komlos, Kristina","Sagadin, Martin","Ursic, Tina","Avsic Zupanc, Tatjana","Petrovec, Miroslav"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277022","week":"202015|Apr 06 - Apr 12","doi":"10.1128/JCM.00599-20","source":"PubMed","locations":["cobas","Branchburg","US","Cobas","kappa","kappa","cobas","cobas"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1663798882986885120,"score":216.69322},{"pmid":32293168,"title":"Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","text":["Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect SARS-CoV-2 spike protein at concentrations of 1 fg/ml in PBS and 100 fg/ml clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/ml) and clinical samples (LOD: 2.42 x 10(2) copies/ml). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling.","ACS Nano","Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il","32293168"],"abstract":["Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect SARS-CoV-2 spike protein at concentrations of 1 fg/ml in PBS and 100 fg/ml clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/ml) and clinical samples (LOD: 2.42 x 10(2) copies/ml). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling."],"journal":"ACS Nano","authors":["Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293168","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acsnano.0c02823","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266295596548096,"score":144.1617},{"pmid":32301745,"title":"Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19).","text":["Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19).","Objectives In December 2019, a novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, China. Laboratory-based diagnostic tests utilized real-time reverse transcriptase polymerase chain reaction (RT-PCR) on throat samples. This study evaluated the diagnostic value to analyzing throat and sputum samples in order to improve accuracy and detection efficiency. Methods Paired specimens of throat swabs and sputum were obtained from 54 cases, and RNA was extracted and tested for 2019-nCoV (equated with SARS-CoV-2) by the RT-PCR assay. Results The positive rates of 2019-nCoV from sputum specimens and throat swabs were 76.9% and 44.2%, respectively. Sputum specimens showed a significantly higher positive rate than throat swabs in detecting viral nucleic acid using the RT-PCR assay (p = 0.001). Conclusions The detection rates of 2019-nCoV from sputum specimens were significantly higher than those from throat swabs. We suggest that sputum would benefit for the detection of 2019-nCoV in patients who produce sputum. The results can facilitate the selection of specimens and increase the accuracy of diagnosis.","Clin Chem Lab Med","Lin, Chenyao","Xiang, Jie","Yan, Mingzhe","Li, Hongze","Huang, Shuang","Shen, Changxin","32301745"],"abstract":["Objectives In December 2019, a novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, China. Laboratory-based diagnostic tests utilized real-time reverse transcriptase polymerase chain reaction (RT-PCR) on throat samples. This study evaluated the diagnostic value to analyzing throat and sputum samples in order to improve accuracy and detection efficiency. Methods Paired specimens of throat swabs and sputum were obtained from 54 cases, and RNA was extracted and tested for 2019-nCoV (equated with SARS-CoV-2) by the RT-PCR assay. Results The positive rates of 2019-nCoV from sputum specimens and throat swabs were 76.9% and 44.2%, respectively. Sputum specimens showed a significantly higher positive rate than throat swabs in detecting viral nucleic acid using the RT-PCR assay (p = 0.001). Conclusions The detection rates of 2019-nCoV from sputum specimens were significantly higher than those from throat swabs. We suggest that sputum would benefit for the detection of 2019-nCoV in patients who produce sputum. The results can facilitate the selection of specimens and increase the accuracy of diagnosis."],"journal":"Clin Chem Lab Med","authors":["Lin, Chenyao","Xiang, Jie","Yan, Mingzhe","Li, Hongze","Huang, Shuang","Shen, Changxin"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301745","week":"202016|Apr 13 - Apr 19","doi":"10.1515/cclm-2020-0187","keywords":["covid-19","sars-cov-2","sputum specimens","throat swabs"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664357978483982336,"score":143.02168},{"pmid":32295896,"title":"Nasal swab sampling for SARS-CoV-2: A convenient alternative in time of nasopharyngeal swab shortage.","text":["Nasal swab sampling for SARS-CoV-2: A convenient alternative in time of nasopharyngeal swab shortage.","Nasopharyngeal swab is the reference sampling method to detect SARS CoV2, as recommended by world Health Organization (WHO) (1).....","J Clin Microbiol","Pere, Helene","Podglajen, Isabelle","Wack, Maxime","Flamarion, Edouard","Mirault, Tristan","Goudot, Guillaume","Hauw-Berlemont, Caroline","Le, Laetitia","Caudron, Eric","Carrabin, Sophie","Rodary, Julien","Ribeyre, Tatiana","Belec, Laurent","Veyer, David","32295896"],"abstract":["Nasopharyngeal swab is the reference sampling method to detect SARS CoV2, as recommended by world Health Organization (WHO) (1)....."],"journal":"J Clin Microbiol","authors":["Pere, Helene","Podglajen, Isabelle","Wack, Maxime","Flamarion, Edouard","Mirault, Tristan","Goudot, Guillaume","Hauw-Berlemont, Caroline","Le, Laetitia","Caudron, Eric","Carrabin, Sophie","Rodary, Julien","Ribeyre, Tatiana","Belec, Laurent","Veyer, David"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295896","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JCM.00721-20","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266651300790274,"score":138.94337}]}